Targets › CHRNA3
1 program from 1 company in 2 trials: 2 Phase 1; Cardiovascular; next expected readout Dec 2026.
Component of neuronal acetylcholine receptors (nAChRs) that function as pentameric, ligand-gated cation channels with high calcium permeability among other activities. nAChRs are excitatory neurotrasnmitter receptors formed by a collection of nAChR subunits known to mediate synaptic transmission in the nervous system and the neuromuscular junction. Each nAchR subunit confers differential attributes to channel…. (UniProt, P32297)
Open in Phaseline: the race on CHRNA3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Vanderbilt University | Trimethaphan Camsylate Neuronal acetylcholine receptor; alpha3/beta4 antagonist | CHRNB4, CHRNA3 | Phase 1 | Multiple System Atrophy; Hypertension | Dec 2026 |
Multiple System Atrophy (1) Hypertension (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.